Saturday 17 October 2026
Export AKAN’s income statement to Excel — free account
Akanda Corp.
AKAN Healthcare Drug Manufacturers Specialty & Generic
Akanda Corp.’s revenue for fiscal 2025 (year ended December 2025) was $258,100.00, down 69.2% from fiscal 2024. Insiders bought in the last twelve months.
1.20
0.11
−8.40%
Follow AKAN
Akanda Corp. (AKAN) P/E ratio
P/E ratio, daily
Annual newest first
| Period | P/E ratio | Change |
|---|
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| SNOA Sonoma Pharmaceuticals, Inc. compare | n/m |
| APUS Apimeds Pharmaceuticals US, Inc. compare | n/m |
| PRFX PainReform Ltd. compare | n/m |
| BTAIQ BioXcel Therapeutics, Inc. compare | n/m |
| RDHL Redhill Biopharma Ltd. compare | n/m |
| IMCC IM Cannabis Corp. compare | n/m |
| YCBD cbdMD, Inc. compare | 41.2× |
| GELS Gelteq Limited compare | — |
| AKAN Akanda Corp. | — |
| Drug Manufacturers Specialty & Generic industry median | 19.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)